LONDON, June 13, 2024 — JMAN Group, a leading commercial data partner for private equity funds and their portfolio companies, has announced the appointment of Jamie Denison-Pender to the Board of Directors to help shape and drive JMAN’s value creation plan (VCP).

Following a minority investment from Baird Capital, Jamie became a Non-Executive Director at JMAN Group. At JMAN, he supports the founders and management team to execute on the VCP, enhance the value proposition, access new markets and scale their critical infrastructure.

Jamie founded Prescient Healthcare Group in 2007 and was CEO until the end of 2022. Under his leadership Prescient grew to become a leading biopharma product and portfolio strategy firm with ~450 employees in offices across the US, Europe and Asia. He successfully led the business through an MBO, two PE events and a tuck in acquisition. By the time he stood down as CEO, Prescient had partnered with nearly 70 biopharma organizations, more than 250 assets and brands and functional leaders across a variety of fields including: CI, medical affairs, clinical development, early commercial, global marketing and market research. The business grew every year and delivered more than 20 quarters of consecutive growth under PE ownership. Baird Capital held Prescient for three and a half years before selling to Bridgepoint Development Capital in early 2021 delivering exceptional shareholder returns.